Orally Bioavailable β3-Adrenergic Receptor Agonists as Potential Therapeutic Agents for Obesityand Type-II Diabetes
- 1 January 2003
- book chapter
- Published by Elsevier in Progress in Medicinal Chemistry
- Vol. 41, 167-194
- https://doi.org/10.1016/s0079-6468(02)41005-3
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Up‐regulation of uncoupling proteins by β‐adrenergic stimulation in L6 myotubesFEBS Letters, 2001
- Substituted oxazole benzenesulfonamides as potent human β3 adrenergic receptor agonistsBioorganic & Medicinal Chemistry Letters, 2000
- Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the β3 agonist SR 58611ABritish Journal of Pharmacology, 1999
- Prodrugs of CL316243: a selective β3-adrenergic receptor agonist for treating obesity and diabetesBioorganic & Medicinal Chemistry Letters, 1999
- L-770,644: A potent and selective human β3 adrenergic receptor agonist with improved oral bioavailabilityBioorganic & Medicinal Chemistry Letters, 1999
- Human β3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamidesBioorganic & Medicinal Chemistry Letters, 1999
- Human β3 andrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamidesBioorganic & Medicinal Chemistry Letters, 1999
- Aryl propanolamines: comparison of activity at human β 3 receptors, rat β3 receptors and rat atrial receptors mediating tachycardiaBritish Journal of Pharmacology, 1999
- Potential anti-diabetic applications of a new molecule with affinity for β3-AdrenoceptorsLife Sciences, 1996
- Distribution of β3-adrenoceptor mRNA in human tissuesEuropean Journal of Pharmacology: Molecular Pharmacology, 1995